ERBB2 and neoplasm: Notably, however, we demonstrate that these mechanisms act at early time points after antibody- or RNAi-mediated HER2 inhibition, indicating distinct intracellular processes rather than the selection of a subset of tumor cells that eventually (re-)grow.